TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29032078
Drug: Pasireotide 10
Normalized name: pasireotide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 10 mg every 4 weeks for 12 months
Study: 29032078
Drug: Pasireotide 30
Normalized name: pasireotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 30 mg every 4 weeks for 12 months
Study: 29032078
Drug: Pasireotide 10
Normalized name: pasireotide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 10 mg
Study: 29032078
Drug: Pasireotide 30
Normalized name: pasireotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 30 mg
Study: 24906587
Drug: D&G preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: D&G preparation (two capsules daily)
Study: 18479954
Drug: Once-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of inhaled glucocorticosteroids
Study: 18479954
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of inhaled glucocorticosteroids
Study: 8712442
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg bupivacaine and saline
Study: 6159698
Drug: Twice per
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice per week radiotherapy (2 fractions per week)
Study: 31722102
Drug: Faculty Development
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faculty Development (FD) program, monthly half-day in-class sessions for 20 months
Study: 19775039
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg ketamine
Study: 19775039
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.15 mg/kg ketamine, 0.5 mg/kg ketamine, normal saline)
Study: 16923362
Drug: Intravenous ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ambroxol (15 mg/kg immediately after birth, then 30 mg/kg daily for 2 days)
Study: 16923362
Drug: Atomizing ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomizing ambroxol (30 mg/kg daily for 2 days)
Study: 16923362
Drug: Intravenous ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ambroxol
Study: 16923362
Drug: Intravenous ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ambroxol and Atomizing ambroxol
Study: 11762561
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan during phase 1 (menses), days 1 to 4
Study: 11762561
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan during phase 2 (follicular), days 6 to 10
Study: 11762561
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan during phase 3 (ovulatory), days 11 to 13
Study: 11762561
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg eletriptan during phase 4 (luteal), days 21 to 24
Study: 7679040
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (doses of 60-65 Gy)
Study: 31612723
Drug: Sufentanil Sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil Sublingual Tablet System (SSTS)
Study: 25761833
Drug: Androgen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen replacement therapy (ART)
Study: 24486335
Drug: Subcutaneous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous ondansetron 4 mg + rHuPH20
Study: 24486335
Drug: Intramuscular ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ondansetron 4 mg
Study: 24570527
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy and irrigation
Study: 20527340
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of 0.25% bupivacaine with saline EVE (n=51)
Study: 20527340
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of 0.25% bupivacaine without saline EVE (n=6)
Study: 20527340
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of 0.25% L-bupivacaine (n=50)
Study: 20527340
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of 0.3% L-bupivacaine (n=50)
Study: 12641681
Drug: premixed midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: premixed midazolam solution
Study: 9007599
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g intravenously every 8 h
Study: 9007599
Drug: Imipenem/cilastatin 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 1 g intravenously every 8 h
Study: 1501736
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione (1,200 mg)
Study: 21422438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (defined as 25(OH)D lower than 20 ng/mL)
Study: 21422438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (defined as 25(OH)D between 20 to 29 ng/mL)
Study: 16850022
Drug: Continuous veno‐venous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous veno‐venous hemodiafiltration (CVVHDF) (1‐2.5 l/h replacement fluid + 1‐1.5 l/h dialysate)
Study: 16850022
Drug: Continuous veno‐venous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous veno‐venous hemofiltration (CVVH) (1‐2.5 l/h replacement fluid)
Study: 10340958
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 40 mg anti-CD4
Study: 10340958
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 0.4 mg anti-CD4
Study: 6702616
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 30 mg/day
Study: 6702616
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 120 mg/day
Study: 6702616
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 240 mg/day
Study: 6702616
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 480 mg/day
Study: 29794523
Drug: Sequential condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential condition
Study: 26995378
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice daily) + P2Y12 inhibitor
Study: 26995378
Drug: DAPT (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (Aspirin 100 mg + P2Y12 inhibitor)
Study: 22009916
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg), zeaxanthin (1 mg), astaxanthin (4 mg) and antioxidants/vitamins supplementation formula
Study: 19560695
Drug: Milrinone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (0.05 mg/kg)
Study: 19560695
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (high dose: 0.43 mg/kg)
Study: 19560695
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (low dose: 0.05 mg/kg)
Study: 10432067
Drug: Low-dose mefloquine-sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose mefloquine-sulfadoxine-pyrimethamine (MSP)
Study: 2182697
Drug: Salbutamol, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol, 2.5 mg administered by nebulization
Study: 23792486
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection + prompt laser with green laser treatment
Study: 23792486
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection + prompt laser with yellow laser treatment
Study: 16409329
Drug: Ca(OH)(2)/CHX (gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)(2)/CHX (gel)
Study: 16409329
Drug: Ca(OH)(2)/CHX (solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)(2)/CHX (solution)
Study: 7479199
Drug: Single, oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral, 20‐mg dose of glipizide
Study: 7479199
Drug: Divided-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided-dose regimens totaling 20 mg each (simulating delayed absorption over 2, 4, and 8 hours)
Study: 378734
Drug: Orphenadrine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orphenadrine (25 mg) and acetaminophen (325 mg) combination
Study: 378734
Drug: Orphenadrine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orphenadrine (25 mg) alone
Study: 378734
Drug: Acetaminophen (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (325 mg) alone
Study: 27780932
Drug: High sPDL1
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sPDL1 (≥0.94 ng/mL)
Study: 27780932
Drug: Low sPDL1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low sPDL1 (<0.94 ng/mL)
Study: 8665876
Drug: Pre‐emptive ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive ketorolac 30 mg administered 30 min before surgical incision
Study: 8665876
Drug: Post‐surgical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐surgical ketorolac 30 mg administered at the end of the surgical procedure
Study: 2194133
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg subcutaneously twice per week for 3 weeks, followed by 1 intramuscular injection of 40 micrograms HB-Vax and 3 subsequent injections of thymopentin)
Study: 27997472
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (including preoperative education about early mobilization with postoperative daily targets)
Study: 26718606
Drug: Luseogliflozin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (2.5 mg/d, increased to 5 mg/d)
Study: 17720628
Drug: Paradoxical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paradoxical therapy
Study: 12126525
Drug: Prednisone group
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone group (14 cases) treated by methimazole 15 approximately 30 mg/d, propranolol 15 approximately 30 mg/d, and prednisone 30 mg/d
Study: 12126525
Drug: Traditional antithyroid
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antithyroid group (10 cases) treated by methimazole 15 approximately 30 mg/d and propranolol 15 approximately 30 mg/d
Study: 9533674
Drug: Incorporating evidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorporating evidence into treatment guidelines
Study: 25645325
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Norditropin(®) SimpleXx)
Study: 23013207
Drug: ETN 50
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 50 mg BIW for 12 weeks followed by QW for 12 weeks (BIW/QW group)
Study: 23013207
Drug: ETN 50
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 50 mg QW for 24 weeks (QW/QW group)
Study: 19371492
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (MI and Control)
Study: 15203476
Drug: Literature and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literature and medicine elective course (8 sessions)
Study: 8513844
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the tablet to the gingiva
Study: 8513844
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the tablet to the palate
Study: 8513844
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the tablet to the cheek
Study: 8513844
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the tablet to the cheek in comatose intubated patients
Study: 27296848
Drug: Fractional third
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional third dose (Fx017M)
Study: 27296848
Drug: Full-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose regimen (012M)
Study: 24754142
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg orally daily for 14 days)
Study: 22261830
Drug: Voluntary counseling/testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary counseling/testing (VC/T) with drug treatment referral
Study: 15825070
Drug: Infliximab maintenance
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab maintenance treatment (5 mg/kg every 8 weeks)
Study: 1952266
Drug: Methacholine (MC)
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methacholine (MC) subcutaneous injections
Study: 1952266
Drug: Atropine (AT)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine (AT) subcutaneous injections
Study: 1952266
Drug: Multi-electrolyte solution
Normalized name: Nutrilyte Multi-Electrolyte Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-electrolyte solution (MES) injections
Study: 1952266
Drug: AT-containing lotion
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-containing lotion
Study: 1952266
Drug: MC-containing lotion
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-containing lotion
Study: 1952266
Drug: MES solution
Normalized name: Limosilactobacillus fermentum ME-3
DrugBank: 2-(N-morpholino)ethanesulfonic acid (DB03814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MES solution
Study: 1952266
Drug: MES solution
Normalized name: Limosilactobacillus fermentum ME-3
DrugBank: 2-(N-morpholino)ethanesulfonic acid (DB03814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MES solution with MC addition
Study: 1952266
Drug: MES solution
Normalized name: Limosilactobacillus fermentum ME-3
DrugBank: 2-(N-morpholino)ethanesulfonic acid (DB03814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MES solution with AT addition
Study: 30306831
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for 8 weeks (responders)
Study: 25800376
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of hip fractures in patients with Parkinson's disease
Study: 25800376
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of hip fractures in patients without Parkinson's disease (Control)
Study: 24898622
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin (1% applied to affected skin, 400 μg/kg, repeated once the following week)
Study: 24898622
Drug: Crotamiton cream
Normalized name: Crotamiton Cream
DrugBank: Crotamiton (DB00265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crotamiton cream 10% (applied twice daily for five consecutive days)
Study: 21696902
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (n=20 patients)
Study: 19390585
Drug: AMA-1/AS01B (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA-1/AS01B (50 microg/0.5 mL)
Study: 19390585
Drug: AMA-1/AS02A (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA-1/AS02A (50 microg/0.5 mL)
Study: 19390585
Drug: AMA-1/AS01B (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA-1/AS01B (10 microg/0.5 mL)
Study: 15298068
Drug: Sublingually administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingually administered cannabis extracts containing approximately equal concentrations of delta9-THC and cannabidiol
Study: 11313175
Drug: CAELYX (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAELYX (50 mg/m² by a 1 h intravenous infusion every 4 weeks)
Study: 11313175
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m² by an intravenous bolus every 3 weeks)
Study: 3131387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LHRH agonist and pure FSH (A2)
Study: 28124506
Drug: Liraglutide up
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide up to 1.8 mg s.c. once daily
Study: 24069472
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment with weekly evaluations
Study: 24069472
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment with twice-weekly evaluations
Study: 24069472
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment with historical controls
Study: 24069472
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment with prospective patients
Study: 20166438
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40, 80, and 120 mg intramuscular tramadol hydrochloride injection
Study: 17266689
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg per day for 4 weeks followed by peg‐IFN 1.0 mug/kg/wk for 24 weeks (Group B)
Study: 15519189
Drug: PDE III
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE III inhibitor (PDE III‐I)
Study: 9890717
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor VIIa (NovoSeven) at doses of 5, 10, 20, 40, 80, 120, 160, 240, or 320 microg/kg
Study: 30628552
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy activities (12 artistic activities)
Study: 25753493
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of alpha-lipoic acid (ALA) supplementation for 12 weeks
Study: 23877706
Drug: Faldaprevir monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir monotherapy
Study: 23877706
Drug: Faldaprevir-PegIFN-RBV triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir-PegIFN-RBV triple therapy
Study: 21883124
Drug: Desmopressin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 1.5 μg
Study: 21883124
Drug: Desmopressin 5
Normalized name: DESMOPRESSIN 55.3MG SUBLINGUAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 5 μg
Study: 21883124
Drug: Desmopressin 15
Normalized name: desmopressin 15 mcg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 15 μg
Study: 17940987
Drug: DHEA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA therapy (150 mg oral daily for 40 days)
Study: 9762002
Drug: Combined lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lower dose group (0.05 or 0.1 IU/kg/day of hGH for 7 days)
Study: 7852551
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with ganciclovir for 2 weeks and then high-dose acyclovir for 2.5 months
Study: 7852551
Drug: High-dose acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acyclovir alone for 3 months
Study: 1183220
Drug: Placebo (antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (antacid containing)
Study: 18165598
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine + rofecoxib 50 mg
Study: 18165598
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine + rofecoxib 50 mg
Study: 16861092
Drug: Fentanyl effervescent
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 100 microg
Study: 16861092
Drug: Fentanyl effervescent
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 200 microg
Study: 16861092
Drug: Fentanyl effervescent
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 400 microg
Study: 16861092
Drug: Fentanyl effervescent
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 800 microg
Study: 15733521
Drug: Isosmotic polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosmotic polyethylene glycol 3350 electrolyte solution